Provenge critic gaining attention after taking shots at study data

Provenge, Dendreon's ($DNDN) pioneering cancer vaccine that disappointed investors last year with its sales, is under fire again. Reuters today spotlights former hedge-fund analyst Marie Huber and her journey to expose holes in the study that supported FDA approval of Provenge for treating prostate cancer in 2010. A scientist by training, Huber has been making a case that the placebo in the pivotal study might have caused harm to men who took the dummy treatment and made Provenge shine by comparison. There are many critics of Huber's analysis, including the doctors who led the Provenge trial. Article

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.